A few biohealth companies made absolutely massive runs in Thursday’s session. With the broad markets near all-time highs, it’s no doubt that part of this push is from the health care sector. The companies 24/7 Wall St. has picked stood out from the rest with big moves, all at least up 10%. We have included information about each company, as well as recent trading activity and the consensus price target.
After the markets closed on Wednesday, Kura Oncology Inc. (NASDAQ: KURA) reported its second-quarter financial results. The company was said to have a net loss of $0.36 per share for the quarter, but the main highlight was its update on its mid-stage trial of tipifarnib in HRAS mutant solid tumors. In the Phase 2 trial, there was “positive clinical activity, including objective responses, has been observed in patients with head and neck squamous cell carcinomas and patients with salivary gland cancer.”
Shares of Kura were trading up 34% at $5.84 on Thursday, with a consensus analyst price target of $16.25 and a 52-week trading range of $2.50 to $25.00.
Aethlon Medical Inc. (NASDAQ: AEMD) announced that it has completed in vitro studies that demonstrate the rapid capture of Zika virus by the Aethlon Hemopurifier. The Hemopurifier is a leading broad-spectrum treatment countermeasure against viral pathogens that are untreatable with or resistant to antiviral drug therapies. Currently, this immunotherapeutic technology is being advanced through an FDA approved human feasibility study. The Zika studies demonstrated a 95% clearance of Zika virus from cell culture fluid in 5.5 hours and an approximate 50% clearance of Zika from human blood serum in 5 hours, with the help of the Hemopurifier.
Shares of Aethlon traded up 27% to $7.90. The consensus price target is $26.00. The 52-week range is $4.02 to $9.09.
Nymox Pharmaceutical Corp. (NASDAQ: NYMX) revealed major progress in its late-stage trial for the treatment of prostate enlargement (BPH) and for low grade prostate cancer. Fexapotide has completed two long-term large Phase 3 BPH studies in the United States. No other new prostate drug injectable currently in development has previously succeeded in enrolling and completing a fully U.S. study close to the size of either of Nymox’s two long-term studies. Additionally, there is no other injectable prostate enlargement drug on the market that has previously been shown to have the excellent long-term safety and efficacy profile of fexapotide.
Nymox shares were up 25% to $2.32, in a 52-week range of $1.62 to $4.37. The consensus price target is $10.25.
Shares of CorMedix Inc. (NYSEMKT: CRMD) surged on Thursday on strong volume, just days after releasing its latest quarterly results. The company had moved over 600,000 shares at the halfway point of the trading day, versus the average daily volume of about 315,000 shares.
In the afternoon, CorMedix was up 24% to $1.75. The consensus price target is $5.25, and the 52-week range is $1.15 to $4.54.
When Ocular Therapeutix Inc. (NASDAQ: OCUL) reported its second-quarter financial results earlier in the week, there was no significant reaction to the $11.4 million quarterly loss (a net loss of $0.40 per share). It was not until Thursday that analysts from JMP Securities weighed in on it with an Outperform rating. The firm sees this as an inflection point for the stock.
Ocular was last seen up 11% at $6.51, with a consensus price target of $33.00 and a 52-week range of $4.04 to $22.92.